# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Rachel Vatnsdal maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price ta...
Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate...
The meeting will be taking place from May 31-June 4 in Chicago. Company will also present at the European Hematology Associatio...
Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate...